Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-017-0788-4) contains supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Breccia, Massimo, Baccarani, Michele, Rosti, Gianantonio, Cottone, Francesco, Cannella, Laura, Guilhot, François, Vignetti, Marco, Efficace, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648464/
https://www.ncbi.nlm.nih.gov/pubmed/29047379
http://dx.doi.org/10.1186/s12955-017-0788-4
Descripción
Sumario:We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-017-0788-4) contains supplementary material, which is available to authorized users.

Ejemplares similares